Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Samir Andrade Mendonça, Réka Lőrincz, Paul Boucher, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 243

Showing 1-25 of 243 citing articles:

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors
Evan Tan, Cara Sze Hui Chin, Zhi Feng Sherman Lim, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 119
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
Majed Ghattas, Garima Dwivedi, Marc Lavertu, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1490-1490
Open Access | Times Cited: 113
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Vivek P. Chavda, Rajashri Bezbaruah, Disha Valu, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 432-432
Open Access | Times Cited: 49
Human health and genetic technology
Hans‐Georg Dederer
Trends in biotechnology (2025) Vol. 43, Iss. 3, pp. 522-532
Open Access | Times Cited: 1
T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses
Elahe Aleebrahim‐Dehkordi, Bahareh Molavi, Melika Mokhtari, et al.
Transplant Immunology (2021) Vol. 70, pp. 101495-101495
Open Access | Times Cited: 90
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines
Parisa Ghasemiyeh, Soliman Mohammadi‐Samani, Negar Firouzabadi, et al.
International Immunopharmacology (2021) Vol. 100, pp. 108162-108162
Open Access | Times Cited: 86
Clinical development and approval of COVID-19 vaccines
Ulrich Kalinke, Dan H. Barouch, Ruben Rizzi, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 5, pp. 609-619
Open Access | Times Cited: 55
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena
Vivek P. Chavda, Rajashri Bezbaruah, Mansi Athalye, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 759-759
Open Access | Times Cited: 55
New Onset Biopsy-Proven Nephropathies after COVID Vaccination
Roberta Fenoglio, Stefania Lalloni, Martina Marchisio, et al.
American Journal of Nephrology (2022) Vol. 53, Iss. 4, pp. 325-330
Open Access | Times Cited: 47
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
COVID-19 Vaccines and Autoimmune Hematologic Disorders
María Eva Mingot‐Castellano, Nora Butta, Mariana Canaro, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 961-961
Open Access | Times Cited: 37
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
Chandramani Singh, Savita Verma, Prabhakar Reddy, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 36
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Gabriela Baldeon Vaca, Michelle Meyer, Ana Cadete, et al.
Science Advances (2023) Vol. 9, Iss. 38
Open Access | Times Cited: 31
Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102140-102140
Open Access | Times Cited: 27
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
Bavesh D Kana, Patrick Arbuthnot, Benjamin K Botwe, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. e288-e300
Open Access | Times Cited: 21
Combined biolistic and cell penetrating peptide delivery for the development of scalable intradermal DNA vaccines
Roizza Beth So, Gang Li, Victoria A. Brentville, et al.
Journal of Controlled Release (2024) Vol. 367, pp. 209-222
Open Access | Times Cited: 7
Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses
Anyeseu Park, Jeong Yoon Lee
The Journal of Microbiology (2024) Vol. 62, Iss. 7, pp. 491-509
Closed Access | Times Cited: 7
Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?
Aniello Maiese, A. Baronti, A Manetti, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 308-308
Open Access | Times Cited: 28
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Aleksandra Anna Zasada, Aniela Darlińska, Aldona Wiatrzyk, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1786-1786
Open Access | Times Cited: 19
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
Jack E. Saunders, Ciarán Gilbride, Stuart Dowall, et al.
EBioMedicine (2023) Vol. 90, pp. 104523-104523
Open Access | Times Cited: 18
Vaccine development for mosquito-borne viral diseases
Zhiwei Huang, Yuxuan Zhang, Hongyu Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines
Sonia Marquez-Martinez, Aneesh Vijayan, Selina Khan, et al.
Current Opinion in Immunology (2023) Vol. 80, pp. 102282-102282
Open Access | Times Cited: 16
An Old Acquaintance: Could Adenoviruses Be Our Next Pandemic Threat?
Gustavo Saint-Pierre, Daniel Conei, Luis Lizama, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 330-330
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top